Nikolaos Settas

Dr. Nikolaos Settas

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
NSNikolaos Settas
Nikolaos Settas
Fabio FauczFabio Faucz
Fabio Faucz
CSConstantine A. Stratakis
Constantine A. Stratakis

3 December 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
NSNikolaos Settas
Nikolaos Settas
RPRebecca Persky
Rebecca Persky
Fabio FauczFabio Faucz
Fabio Faucz
NSNicole Sheanon
Nicole Sheanon
AVAntonis Voutetakis
Antonis Voutetakis
CSConstantine A Stratakis
Constantine A Stratakis
Context Multiple autosomal recessive genes have been etiologically linked to primary adrenal insufficiency (PAI). Recently, sphingosine-1-phosphate lyase 1 (SGPL1) gene mutations were recognized as a cause of steroid-resistant nephrotic syndrome type 14 (NPHS14), a sphingolipidosis with multisystemic manifestations, including PAI. Objective To check if SGPL1 mutations are involved in the pathogenesis of PAI in patients who do not exhibit nephrotic syndrome. Methods Sequencing of the SGPL1 gene in 21 patients with familial glucocorticoid disease or triple A syndrome. Results We identified two missense SGPL1 variants in four patients, two of whom were first cousins. We describe in detail the proband, a boy born to Saudi Arabian consanguineous parents with a homozygous c.665G>A, p.R222Q SGPL1 variant. The patient presented with hypoglycemia and seizures at age 2 years and was ultimately diagnosed with PAI (isolated glucocorticoid deficiency). Brain MRI showed abnormalities in the basal ganglia consistent with a degenerative process albeit the patient had no neurologic symptoms. Conclusions New genetic causes of PAI continue to be identified. We suggest that screening for SGPL1 mutations should not be reserved only for patients with nephrotic syndrome but may also include patients with PAI who lack other clinical manifestations of NPHS14 because, in certain cases, kidney disease and accompanying features might develop. Timely diagnosis of this specific sphingolipidosis while the kidneys still function normally can lead to prompt initiation of therapy and improve outcome.

1 November 2020 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
SEStephanie Espiard
Stephanie Espiard
LDLudivine Drougat
Ludivine Drougat
NSNikolaos Settas
Nikolaos Settas
SHSara Haydar
Sara Haydar
KBKerstin Bathon
Kerstin Bathon
CSConstantine A Stratakis
Constantine A Stratakis
Genetic variants in components of the protein kinase A (PKA) enzyme have been associated with various defects and neoplasms in the context of Carney complex (CNC) and in isolated cases, such as in primary pigmented nodular adrenocortical disease (PPNAD), cortisol-producing adrenal adenomas (CPAs), and various cancers. PRKAR1A mutations have been found in subjects with impaired cAMP-dependent signaling and skeletal defects; bone tumors also develop in both humans and mice with PKA abnormalities. We studied the PRKACB gene in 148 subjects with PPNAD and related disorders, who did not have other PKA-related defects and identified two subjects with possibly pathogenic PRKACB gene variants and unusual bone and endocrine phenotypes. The first presented with bone and other abnormalities and carried a de novo c.858_860GAA (p.K286del) variant. The second subject carried the c.899C>T (p.T300M or p.T347M in another isoform) variant and had a PPNAD-like phenotype. Both variants are highly conserved in the PRKACB gene. In functional studies, the p.K286del variant affected PRKACB protein stability and led to increased PKA signaling. The p.T300M variant did not affect protein stability or response to cAMP and its pathogenicity remains uncertain. We conclude that PRKACB germline variants are uncommon but may be associated with phenotypes that resemble those of other PKA-related defects. However, detailed investigation of each variant is needed as PRKACB appears to be only rarely affected in these conditions, and variants such as p.T300M maybe proven to be clinically insignificant, whereas others (such as p.K286del) are clearly pathogenic and may be responsible for a novel syndrome, associated with endocrine and skeletal abnormalities.

8 September 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
LDLudivine Drougat
Ludivine Drougat
NSNikolaos Settas
Nikolaos Settas
CRCristina L. Ronchi
Cristina L. Ronchi
KBKerstin Bathon
Kerstin Bathon
DCDavide Calebiro
Davide Calebiro
CSConstantine A. Stratakis
Constantine A. Stratakis

7 December 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
MSMarzia Scortegagna
Marzia Scortegagna
ABAnnabel Berthon
Annabel Berthon
NSNikolaos Settas
Nikolaos Settas
AGAndreas Giannakou
Andreas Giannakou
GGGuillermina Garcia
Guillermina Garcia
ZRZe’EV A. Ronai
Ze’EV A. Ronai
Primary and secondary hypertension are major risk factors for cardiovascular disease, the leading cause of death worldwide. Elevated secretion of aldosterone resulting from primary aldosteronism (PA) is a key driver of secondary hypertension. Here, we report an unexpected role for the ubiquitin ligase Siah1 in adrenal gland development and PA. Siah1a –/– mice exhibit altered adrenal gland morphology, as reflected by a diminished X-zone, enlarged medulla, and dysregulated zonation of the glomerulosa as well as increased aldosterone levels and aldosterone target gene expression and reduced plasma potassium levels. Genes involved in catecholamine biosynthesis and cAMP signaling are upregulated in the adrenal glands of Siah1a –/– mice, while genes related to retinoic acid signaling and cholesterol biosynthesis are downregulated. Loss of Siah1 leads to increased expression of the Siah1 substrate PIAS1, an E3 SUMO protein ligase implicated in the suppression of LXR, a key regulator of cholesterol levels in the adrenal gland. In addition, SIAH1 sequence variants were identified in patients with PA; such variants impaired SIAH1 ubiquitin ligase activity, resulting in elevated PIAS1 expression. These data identify a role for the Siah1-PIAS1 axis in adrenal gland organization and function and point to possible therapeutic targets for hyperaldosteronism.

18 December 2020 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ABAnnabel Berthon
Annabel Berthon
NSNikolaos Settas
Nikolaos Settas
ADAngela Delaney
Angela Delaney
AGAndreas Giannakou
Andreas Giannakou
ADAndrew Demidowich
Andrew Demidowich
CSConstantine A. Stratakis
Constantine A. Stratakis
Knockout mice for the kisspeptin receptor, Kiss1r (Kiss1r−/−) and its ligand kisspeptin, Kiss1 (Kiss1−/−) replicate the phenotype of isolated hypogonadotropic hypogonadism (IHH) associated with variants of these genes in humans. A recent report suggests that kisspeptin may be involved in human fetal adrenocortical development and function. Herein, we characterized the adrenal function and morphology in Kiss1−/− mice that do not go through normal puberty. Two fetal markers were expressed in eosinophilic cells potentially derived from the X-zone that should disappear at puberty in male mice and during the first pregnancy in female animals. Although the hypercorticosteronism observed in Kiss1−/− females corrected overtime, hyperaldosteronism persisted at 14 months and correlated with the overexpression of Star. To determine if KISS1 and KISS1R genes are involved in the development of primary aldosteronism (PA) and hypercortisolism [Cushing’s syndrome (CS)] in humans, we sequenced these 2 genes in 65 patients with PA and/or CS. Interestingly, a patient with CS presented with a germline KISS1 variant (p.H90D, rs201073751). We also found three rare variants in the KISS1R gene in three patients with PA: p.C95W (rs141767649), p.A189T (rs73507527) and p.R229R (rs115335009). The two missense variants have been previously associated with IHH. Our findings suggest that KISS1 may play a role in adrenal function in mice and possibly adrenocortical steroid hormone secretion in humans, beyond its recently described role in human fetal adrenocortical development.